FOXA3 and metabolic dysfunction-associated steatotic liver disease: This study confirmed that FOXA3 links stress to NAFLD progression, demonstrating the importance of the FOXA3/SREBP-1c transcriptional axis in NAFLD progression, proposing that FOXA3 is a potential therapeutic target for FLD [66].